SANDOZ DOLUTEGRAVIR DIN 02501457
Status: Approved
Holder: SANDOZ CANADA INCORPORATED
Health Canada record
| Active ingredient(s) | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | J05AJ03 DOLUTEGRAVIR |
|---|
| Original market date | |
|---|
| Current status date | 29-Apr-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02491753 | DOVATO | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; LAMIVUDINE 300 MG | Marketed |
| 02475774 | JULUCA | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MG | Marketed |
| 02556782 | PMS-DOLUTEGRAVIR | PHARMASCIENCE INC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG | Marketed |
| 02511517 | TIVICAY | VIIV HEALTHCARE ULC | Tablet For Suspension | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 5 MG | Marketed |
| 02414945 | TIVICAY | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG | Marketed |
| 02430932 | TRIUMEQ | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Marketed |
| 02461226 | TIVICAY | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 25 MG | Cancelled Post Market |
| 02461218 | TIVICAY | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37425 | 2026-04-29 | Abbreviated New Drug Submission (ANDS) | |
Request a quote for SANDOZ DOLUTEGRAVIR
How to read a Canadian DIN record